Japanese player Sawai Pharmaceutical Co., Ltd. has unveiled plans to build a new solid dosage form facility at its local Daini Kyushu site, citing an increase in demand for its products that has followed supply and quality issues that have plagued the Japanese generics industry this year, as well as to “strengthen production capacity in response to further market expansion of generic drugs in the future.”
“To the current annual production capacity of 2.5 billion tablets at the factory, an annual production capacity of 2 billion...
